研報掘金丨德邦證券:開立醫療Q1業績超預期,預計進入中高速發展期 維持“買入”評級
格隆匯5月12日丨近日,開立醫療(300633.SZ)發佈23Q1營業收入4.73億元,同比增長27.63%;歸母淨利潤1.38億元,同比增長171.11%。德邦證券研報指出,公司業績高增能力持續驗證,淨利潤大幅增長171%,大超預期。預計進入中高速發展期:軟鏡持續高增長,硬鏡、高端超聲有望快速放量,此外,亮點不止看軟鏡,高端產品密集上市,後續增長動能強勁。該行稱,公司國產內鏡龍頭地位穩固,有望打造中國版“奧林巴斯”,業績高速釋放能力持續獲得驗證,內鏡、高端超聲增長動能強勁。預計公司2023-25年營業收入分別為22.6/28.8/36.7億,同比增速為28%/27.9%/27.1%;歸母淨利潤分別為5.3/6.88/8.94億,同比增速為43.4%/29.7%/29.9%。對應PE分別為45/35/27倍。維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.